40592-V49H5-B Search Results


multimerized biotinylated delta variant rbd protein  (Sino Biological)
90
Sino Biological multimerized biotinylated delta variant rbd protein
WT spike-generated vaccine response can recognize B.1.617.2 spike, and most antibody responses wane over time. A, Twenty randomly chosen lymphoma patient samples positive for blocking activity against <t>WT-RBD</t> were tested against B.1.617.2-variant RBD in parallel and RBD–ACE2 binding inhibition against the two variants was compared. B, Representative flow cytometry results from peripheral blood taken 4 months after vaccination from a patient with lymphoma. Memory B cells are pregated on positivity for CD19, CD20, and CD27 and negativity for IgD. Plots show negative control (left), or binding of <t>biotinylated</t> RBD, either WT (middle) or B1.617.2 <t>delta</t> (right), <t>multimerized</t> by streptavidin–PE prior to staining. Streptavidin–BV986 identifies any nonspecific streptavidin binding. C, Summary of results from four patients with lymphoma (Lym1–4) who had circulating memory B cells and were tested for binding to WT- and delta-RBD. Paired data for blocking activity (D; n = 19) and total anti-spike IgG (E; n = 61) from participants who had a positive result at 1-month postvaccination and for whom samples were available from a later time point approximately 4 months postvaccination. Dashed lines represent validated cutoffs for positivity. RU, relative units. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Multimerized Biotinylated Delta Variant Rbd Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/40592-V49H5-B/SARS-CoV-2+Spike+RBD+(K417N%2C+L452R%2C+T478K)+Protein+(His+%26+AVI+Tag)%2C+Biotinylated/pmc09610898-260-28-33
Average 90 stars, based on 1 article reviews
multimerized biotinylated delta variant rbd protein - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


WT spike-generated vaccine response can recognize B.1.617.2 spike, and most antibody responses wane over time. A, Twenty randomly chosen lymphoma patient samples positive for blocking activity against WT-RBD were tested against B.1.617.2-variant RBD in parallel and RBD–ACE2 binding inhibition against the two variants was compared. B, Representative flow cytometry results from peripheral blood taken 4 months after vaccination from a patient with lymphoma. Memory B cells are pregated on positivity for CD19, CD20, and CD27 and negativity for IgD. Plots show negative control (left), or binding of biotinylated RBD, either WT (middle) or B1.617.2 delta (right), multimerized by streptavidin–PE prior to staining. Streptavidin–BV986 identifies any nonspecific streptavidin binding. C, Summary of results from four patients with lymphoma (Lym1–4) who had circulating memory B cells and were tested for binding to WT- and delta-RBD. Paired data for blocking activity (D; n = 19) and total anti-spike IgG (E; n = 61) from participants who had a positive result at 1-month postvaccination and for whom samples were available from a later time point approximately 4 months postvaccination. Dashed lines represent validated cutoffs for positivity. RU, relative units. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Journal: Blood Cancer Discovery

Article Title: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity

doi: 10.1158/2643-3230.BCD-21-0222

Figure Lengend Snippet: WT spike-generated vaccine response can recognize B.1.617.2 spike, and most antibody responses wane over time. A, Twenty randomly chosen lymphoma patient samples positive for blocking activity against WT-RBD were tested against B.1.617.2-variant RBD in parallel and RBD–ACE2 binding inhibition against the two variants was compared. B, Representative flow cytometry results from peripheral blood taken 4 months after vaccination from a patient with lymphoma. Memory B cells are pregated on positivity for CD19, CD20, and CD27 and negativity for IgD. Plots show negative control (left), or binding of biotinylated RBD, either WT (middle) or B1.617.2 delta (right), multimerized by streptavidin–PE prior to staining. Streptavidin–BV986 identifies any nonspecific streptavidin binding. C, Summary of results from four patients with lymphoma (Lym1–4) who had circulating memory B cells and were tested for binding to WT- and delta-RBD. Paired data for blocking activity (D; n = 19) and total anti-spike IgG (E; n = 61) from participants who had a positive result at 1-month postvaccination and for whom samples were available from a later time point approximately 4 months postvaccination. Dashed lines represent validated cutoffs for positivity. RU, relative units. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Article Snippet: A total of 1 to 2 × 10 6 cells were washed and stained with biotinylated SARS-Cov-2 Spike RBD protein (Sino Biological, #40592-V08B-B), multimerized with streptavidin–PE or the multimerized biotinylated delta-variant RBD protein (Sino Biological, #40592-V49H5-B).

Techniques: Generated, Blocking Assay, Activity Assay, Variant Assay, Binding Assay, Inhibition, Flow Cytometry, Negative Control, Staining